To further illustrate the clinical relevance of our data, we referred to a published drug database (https://www.cancerrxgene.org/) and identified ten proteins that showed high expression in STS and could be targeted by FDA-approval drugs, including ACLY, CDK4, PGD, and etc. (Supplementary Fig. 4C). This evidence concerns the gene CDK4 and telomere syndrome.